From Diagnostic Limitations to Precision Medicine: AI-Enhanced CRISPR for Gallbladder Cancer Detection
DOI:
https://doi.org/10.58445/rars.3695Keywords:
Gallbladder Cancer, CRISPR, Artificial Intelligence, DiagnosticsAbstract
Gallbladder cancer (GBC) is a highly lethal disease, often diagnosed at advanced stages due to vague symptoms and lack of reliable screening methods. This paper explores how AI-enhanced CRISPR can contribute to an earlier and more precise detection of GBC. It first details the diagnostic challenges of GBC. Next, it introduces CRISPR, a genome editing technology including its ability to identify genetic alterations associated with cancer. Then, it explores how CRISPR has revolutionised medical diagnostics and treatment, particularly when combined with AI. AI can improve accuracy by reducing off-target effects and guiding the RNA, helping improve accuracy. It will also examine existing AI-integrated CRISPR tools. We hypothesize that this AI-enhanced CRISPR-based approach will enable the development of more precise and sensitive diagnostic systems, offering a critical opportunity to improve early detection of GBC and patient outcomes.
References
Abudayyeh, O. O., Gootenberg, J. S., Konermann, S., Joung, J., Slaymaker, I. M., Cox, D. B., Shmakov, S., Makarova, K. S., Semenova, E., Minakhin, L., Severinov, K., Regev, A., Lander, E. S., Koonin, E. V., & Zhang, F. (2016). C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science, 353(6299), aaf5573. https://doi.org/10.1126/science.aaf5573
Bardelli, A., & Pantel, K. (2017). Liquid biopsies in cancer patients: Opportunities and challenges. Nature Reviews Clinical Oncology, 14(9), 531–548. https://doi.org/10.1038/nrclinonc.2017.9
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424. https://doi.org/10.3322/caac.21492
Broughton, J. P., Deng, X., Yu, G., Fasching, C. L., Servellita, V., Singh, J., Miao, X., Streithorst, J. A., Granados, A., Sotomayor-Gonzalez, A., Zorn, K., Gopez, A. A., Hsu, E., Gu, W., Miller, S., Pan, C. Y., Guevara, H., Wadford, D. A., & Chiu, C. Y. (2020). CRISPR–Cas12-based detection of SARS-CoV-2. Nature Biotechnology, 38(7), 870–874. https://doi.org/10.1038/s41587-020-0513-4
Char, D. S., Shah, N. H., & Magnus, D. (2018). Implementing machine learning in health care—addressing ethical challenges. New England Journal of Medicine, 378(11), 981–983. https://doi.org/10.1056/NEJMp1714229
Chen, J. S., Ma, E., Harrington, L. B., Da Costa, M., Tian, X., Palefsky, J. M., & Doudna, J. A. (2018). CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science, 360(6387), 436–439. https://doi.org/10.1126/science.aar6245
Chen, Y., Li, S., & Li, J. (2020). Emerging CRISPR-based diagnostics. Trends in Biotechnology, 38(9), 1008–1021. https://doi.org/10.1016/j.tibtech.2020.02.012
Chuai, G., Wang, Q., Liu, Q., et al. (2018). DeepCRISPR: Optimized CRISPR guide RNA design by deep learning. Genome Biology, 19(1), 80. https://doi.org/10.1186/s13059-018-1465-5
Cleveland Clinic. (n.d.). Gallbladder cancer. https://my.clevelandclinic.org/health/diseases/17013-gallbladder-cancer
Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., Virgin, H. W., Listgarten, J., & Root, D. E. (2016). Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nature Biotechnology, 34(2), 184–191. https://doi.org/10.1038/nbt.3437
Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. Science, 346(6213), 1258096. https://doi.org/10.1126/science.1258096
Dragt, E. (2026). CRISPR/Cas9 Gene Editing. https://app.biorender.com/biorender-templates/details/t-5f873df466346900a43c6db1-crisprcas9-gene-editing
Esteva, A., Kuprel, B., Novoa, R. A., Ko, J., Swetter, S. M., Blau, H. M., & Thrun, S. (2017). Dermatologist-level classification of skin cancer with deep neural networks. Nature, 542(7639), 115–118. https://doi.org/10.1038/nature21056
Gootenberg, J. S., Abudayyeh, O. O., Kellner, M. J., Joung, J., Collins, J. J., & Zhang, F. (2018). Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. Science, 360(6387), 439–444. https://doi.org/10.1126/science.aaq0179
Heitzer, E., Haque, I. S., Roberts, C. E. S., & Speicher, M. R. (2019). Current and future perspectives of liquid biopsies in genomics-driven oncology. Genome Medicine, 11(1), 1–13. https://doi.org/10.1186/s13073-019-0686-9
Hundal, R., & Shaffer, E. A. (2014). Gallbladder cancer: Epidemiology and outcome. Clinical Epidemiology, 6, 99–109. https://pubmed.ncbi.nlm.nih.gov/24634588/
Jolany Vangah, S., Katalani, C., Boone, H. A., et al. (2020). CRISPR-Based Diagnosis of Infectious and Noninfectious Diseases. Biological Procedures Online, 22, 22. https://doi.org/10.1186/s12575-020-00135-3
Kalra, N., Suri, S., Gupta, R., & Khandelwal, N. (2019). Imaging of gallbladder carcinoma. Radiologic Clinics of North America, 57(3), 487–503. https://doi.org/10.1016/j.rcl.2019.01.004
Kaminski, M. M., Abudayyeh, O. O., Gootenberg, J. S., Zhang, F., & Collins, J. J. (2021). CRISPR-based diagnostics. Nature Biomedical Engineering. https://doi.org/10.1038/s41551-021-00760-7
Kellner, M. J., Koob, J. G., Gootenberg, J. S., Abudayyeh, O. O., & Zhang, F. (2019). SHERLOCK: Nucleic acid detection with CRISPR nucleases. Nature Protocols, 14(10), 2986–3012. https://doi.org/10.1038/s41596-019-0210-2
Kim, H. K., Min, S., Song, M., Jung, S., Choi, J. W., Kim, Y., Lee, S., Yoon, S., & Kim, H. H. (2019). Deep learning improves prediction of CRISPR–Cas9 activity. Nature Biotechnology, 37(3), 239–241. https://doi.org/10.1038/s41587-018-0019-3
Lazcano-Ponce, E. C., Miquel, J. F., Muñoz, N., Herrero, R., Ferrecio, C., Wistuba, I. I., Alonso de Ruiz, P., Urista, G. A., & Nervi, F. (2001). Epidemiology and molecular pathology of gallbladder cancer. CA: A Cancer Journal for Clinicians, 51(6), 349–364. https://doi.org/10.3322/canjclin.51.6.349
Ledford, H. (2020). CRISPR gene editing produces first results in patients. Nature, 579(7798), 185–186. https://doi.org/10.1038/d41586-020-00655-8
Li, S. Y., Cheng, Q. X., Liu, J. K., Nie, X. Q., Zhao, G. P., & Wang, J. (2018). CRISPR-Cas12a-assisted nucleic acid detection. Cell Discovery, 4(1), 20. https://doi.org/10.1038/s41421-018-0028-z
Mayo Clinic. (2018, July 24). CRISPR explained [Video]. YouTube. https://www.youtube.com/watch?v=UKbrwPL3wXE
MD Anderson Cancer Center. (n.d.). Gallbladder cancer: 9 facts about symptoms, diagnosis and treatment. https://www.mdanderson.org/cancerwise/gallbladder-cancer--9-facts-about-symptoms--diagnosis--treatment.h00-159624168.html
Okamoto, A., Yamamoto, H., & Yoshida, M. (2019). Genetic alterations and molecular pathways in gallbladder cancer. Cancers, 11(9), 1–15. https://doi.org/10.3390/cancers11091338
Regassa, S. L. (2026). Lateral flow based CRISPR-Cas12a detection. https://app.biorender.com/profile/template/details/t-66d87689a1167d424e15b04a-lateral-flow-based-crispr-cas12a-detection
Srivastava, A., Pal, R., & Tiwari, R. (2018). Role of long non-coding RNAs in cancer progression. Oncology Letters, 15(4), 4565–4572. https://doi.org/10.3892/ol.2018.7890
Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. Nature Medicine, 25(1), 44–56. https://doi.org/10.1038/s41591-018-0300-7
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017). Liquid biopsies come of age: Towards implementation of circulating tumour DNA. Nature Reviews Cancer, 17(4), 223–238. https://doi.org/10.1038/nrc.2017.7
Wang, D., Wang, L., & Zou, X. (2020). Machine learning for CRISPR guide RNA design and off-target prediction. Nature Machine Intelligence, 2(1), 38–47. https://doi.org/10.1038/s42256-019-0134-0
Wang, D., Zhang, C., & Gao, G. (2019). CRISPR/Cas9 in genome editing and beyond. Annual Review of Biochemistry, 88, 227–264. https://doi.org/10.1146/annurev-biochem-013118-111552
Wang, J., Zhou, Y., Fei, X., Chen, X., & Chen, Y. (2022). Circulating microRNAs as biomarkers for gallbladder cancer diagnosis and prognosis. Frontiers in Oncology, 12, 1–12. https://doi.org/10.3389/fonc.2022.824989
Wessels, H.-H., Stirn, A., Méndez-Mancilla, A., Kim, E.J., Hart, S.K., Knowles, D.A. and Sanjana, N.E. (2023). Prediction of on-target and off-target activity of CRISPR–Cas13d guide RNAs using deep learning. Nature Biotechnology. https://www.nature.com/articles/s41587-023-01830-8
Xiang, X., Corsi, G. I., & Anthon, C. (2021). CRISPR-Cas systems and machine learning: A new era of genome editing. Briefings in Bioinformatics, 22(4), bbaa247. https://doi.org/10.1093/bib/bbaa247
Downloads
Posted
Categories
License
Copyright (c) 2026 Research Archive of Rising Scholars
This work is licensed under a Creative Commons Attribution 4.0 International License.
